CDA | Evidence Driven
CDA | Evidence Driven

belantamab mafodotin, bortezomib, dexamethasone

Details

Generic Name:
belantamab mafodotin, bortezomib, dexamethasone
Project Status:
Pending
Therapeutic Area:
Previously treated multiple myeloma
Manufacturer:
GlaxoSmithKline Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0379-000
Call for patient/clinician input closed:
Tumour Type:
Myeloma
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​​Belantamab mafodotin is indicated for the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Belantamab mafodotin is indicated for the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : August 7, 2024